Description

JKC363, a selective melanocortin MC4 receptor antagonist, has a 90-fold higher affinity at the MC4 receptor (IC50=0.5 nM) than at the MC3 receptor (44.9 nM). JKC-363 blocks the stimulatory effect of α-MSH on TRH release. Anti-hyperalgesic effect[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)–Neuroscience-Neuromodulation–C69H91N19O16S2—-[1]Kim MS, et al. Effects of melanocortin receptor ligands on thyrotropin-releasing hormone release: evidence for the differential roles of melanocortin 3 and 4 receptors. J Neuroendocrinol. 2002;14(4):276-282.|[2]Bellasio S, et al. Melanocortin receptor agonists and antagonists modulate nociceptive sensitivity in the mouse formalin test. Eur J Pharmacol. 2003;482(1-3):127-132.–436083-30-6–1506.71–99.55–C(C=1C=2C(NC1)=CC=CC2)[C@@H]3NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CC4=CC5=C(C=C4)C=CC=C5)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H](CCC(O)=O)NC(=O)CCSSC[C@@H](C(=O)N7[C@H](C(=O)N8[C@H](C(N[C@H](C(N[C@@H](CC(O)=O)C(N)=O)=O)CCCCN)=O)CCC8)CCC7)NC(=O)CNC3=O–Neurological Disease–DMSO : 50 mg/mL (ultrasonic)–Melanocortin Receptor–MC4R–GPCR/G Protein;Neuronal Signaling–Peptides